Amedeo Smart

Free Medical Literature Service


 

Amedeo

Alzheimer's Disease

  Free Subscription

Articles published in
Alzheimers Dement
    September 2022
  1. HARTZ SM, Mozersky J, Schindler SE, Linnenbringer E, et al
    A flexible modeling approach for biomarker-based computation of absolute risk of Alzheimer's disease dementia.
    Alzheimers Dement. 2022 Sep 30. doi: 10.1002/alz.12781.
    >> Share

  2. SCHAEVERBEKE J, Tome SO, Ronisz A, Ospitalieri S, et al
    Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes.
    Alzheimers Dement. 2022 Sep 28. doi: 10.1002/alz.12794.
    >> Share

  3. KATABATHULA S, Davis PB, Xu R
    Comorbidity-driven multi-modal subtype analysis in mild cognitive impairment of Alzheimer's disease.
    Alzheimers Dement. 2022 Sep 27. doi: 10.1002/alz.12792.
    >> Share

  4. WEAVER DF
    Alzheimer's disease as an innate autoimmune disease (AD(2) ): A new molecular paradigm.
    Alzheimers Dement. 2022 Sep 27. doi: 10.1002/alz.12789.
    >> Share

  5. LIU KY, Thambisetty M, Howard R
    How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?
    Alzheimers Dement. 2022 Sep 26. doi: 10.1002/alz.12788.
    >> Share

  6. PICHET BINETTE A, Janelidze S, Cullen N, Dage JL, et al
    Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance.
    Alzheimers Dement. 2022 Sep 24. doi: 10.1002/alz.12787.
    >> Share

  7. VETELEANU A, Pape S, Davies K, Kodosaki E, et al
    Complement dysregulation and Alzheimer's disease in Down syndrome.
    Alzheimers Dement. 2022 Sep 23. doi: 10.1002/alz.12799.
    >> Share

  8. YIN L, Zhou J, Li T, Wang X, et al
    Inhibition of the dopamine transporter promotes lysosome biogenesis and ameliorates Alzheimer's disease-like symptoms in mice.
    Alzheimers Dement. 2022 Sep 21. doi: 10.1002/alz.12776.
    >> Share


  9. Alzheimer's Association launches ALZ-NET: A long-term data collection and sharing network for new treatments.
    Alzheimers Dement. 2022 Sep 12. doi: 10.1002/alz.12782.
    >> Share

  10. JUTTEN RJ, Papp KV, Hendrix S, Ellison N, et al
    Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.
    Alzheimers Dement. 2022 Sep 10. doi: 10.1002/alz.12773.
    >> Share

  11. MATTKE S, Correa Dos Santos Filho O, Hanson M, Mateus EF, et al
    Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer's disease treatment.
    Alzheimers Dement. 2022 Sep 5. doi: 10.1002/alz.12778.
    >> Share

  12. SKILLBACK T, Blennow K, Zetterberg H, Skoog J, et al
    Slowing gait speed precedes cognitive decline by several years.
    Alzheimers Dement. 2022;18:1667-1676.
    >> Share

    August 2022
  13. JIANG L, Li JC, Tang BS, Guo JF, et al
    Lack of bidirectional association between age-related macular degeneration and Alzheimer's disease: A Mendelian randomization study.
    Alzheimers Dement. 2022 Aug 25. doi: 10.1002/alz.12775.
    >> Share

  14. LUTZ MW, Khachaturian AS, Zetterberg H, Blennow K, et al
    Biomarkers of Alzheimer syndrome and related dementias: A&D author's guide.
    Alzheimers Dement. 2022 Aug 25. doi: 10.1002/alz.12772.
    >> Share

  15. FRIKKE-SCHMIDT R, Hegazy SH, Rasmussen IJ, Nordestgaard BG, et al
    Observational and genetic studies of C-reactive protein levels and risk of Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 21. doi: 10.1002/alz.12742.
    >> Share

  16. RAFII MS, Sperling RA, Donohue MC, Zhou J, et al
    The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 15. doi: 10.1002/alz.12748.
    >> Share

  17. PALMQVIST S, Stomrud E, Cullen N, Janelidze S, et al
    An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
    Alzheimers Dement. 2022 Aug 11. doi: 10.1002/alz.12751.
    >> Share

  18. LANGBAUM JB, Zissimopoulos J, Au R, Bose N, et al
    Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
    Alzheimers Dement. 2022 Aug 10. doi: 10.1002/alz.12737.
    >> Share

  19. OLCHANSKI N, Daly AT, Zhu Y, Breslau R, et al
    Alzheimer's disease medication use and adherence patterns by race and ethnicity.
    Alzheimers Dement. 2022 Aug 8. doi: 10.1002/alz.12753.
    >> Share

  20. SCHINDLER SE, Li Y, Li M, Despotis A, et al
    Using Alzheimer's disease blood tests to accelerate clinical trial enrollment.
    Alzheimers Dement. 2022 Aug 7. doi: 10.1002/alz.12754.
    >> Share

  21. WANG J, Guo C, Meng Z, Zwan MD, et al
    Testing the link between isoaspartate and Alzheimer's disease etiology.
    Alzheimers Dement. 2022 Aug 4. doi: 10.1002/alz.12735.
    >> Share

  22. MOLONEY CM, Labuzan SA, Crook JE, Siddiqui H, et al
    Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain.
    Alzheimers Dement. 2022 Aug 3. doi: 10.1002/alz.12749.
    >> Share

  23. PETERSEN RC, Graf A, Carrillo MC, Weber CJ, et al
    Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints.
    Alzheimers Dement. 2022;18:1586.
    >> Share

  24. HACHINSKI V
    The comprehensive, customized, cost-effective approach (CCCAP) to prevention of dementia.
    Alzheimers Dement. 2022;18:1565-1568.
    >> Share

  25. LENNON JC, Aita SL, Bene VAD, Rhoads T, et al
    Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation.
    Alzheimers Dement. 2022;18:1461-1471.
    >> Share

  26. PERLUIGI M, Picca A, Montanari E, Calvani R, et al
    Aberrant crosstalk between insulin signaling and mTOR in young Down syndrome individuals revealed by neuronal-derived extracellular vesicles.
    Alzheimers Dement. 2022;18:1498-1510.
    >> Share

  27. PAJEWSKI NM, Elahi FM, Tamura MK, Hinman JD, et al
    Plasma amyloid beta, neurofilament light chain, and total tau in the Systolic Blood Pressure Intervention Trial (SPRINT).
    Alzheimers Dement. 2022;18:1472-1483.
    >> Share

    July 2022
  28. HANSSON O, Edelmayer RM, Boxer AL, Carrillo MC, et al
    The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 31. doi: 10.1002/alz.12756.
    >> Share

  29. NOTARIANNI E
    Risk association between midlife lipid and glucose levels and future Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 28. doi: 10.1002/alz.12738.
    >> Share

  30. LOZUPONE M, Imbimbo BP, Balducci C, Lo Vecchio F, et al
    Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease?
    Alzheimers Dement. 2022 Jul 28. doi: 10.1002/alz.12728.
    >> Share

  31. MAHAPATRA G, Gao Z, Bateman JR 3rd, Lockhart SN, et al
    Blood-based bioenergetic profiling reveals differences in mitochondrial function associated with cognitive performance and Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 23. doi: 10.1002/alz.12731.
    >> Share

  32. BEYER L, Stocker H, Rujescu D, Holleczek B, et al
    Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years.
    Alzheimers Dement. 2022 Jul 19. doi: 10.1002/alz.12745.
    >> Share

  33. LIU H, Xie Y, Wang X, Abboud MI, et al
    Exploring links between 2-oxoglutarate-dependent oxygenases and Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 19. doi: 10.1002/alz.12733.
    >> Share

  34. BATRA R, Arnold M, Worheide MA, Allen M, et al
    The landscape of metabolic brain alterations in Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 13. doi: 10.1002/alz.12714.
    >> Share

  35. WANG JT, Xu G, Ren RJ, Wang Y, et al
    The impacts of health insurance and resource on the burden of Alzheimer's disease and related dementias in the world population.
    Alzheimers Dement. 2022 Jul 12. doi: 10.1002/alz.12730.
    >> Share

  36. LIN Z, Lim C, Jiang D, Soldan A, et al
    Longitudinal changes in brain oxygen extraction fraction (OEF) in older adults: Relationship to markers of vascular and Alzheimer's pathology.
    Alzheimers Dement. 2022 Jul 6. doi: 10.1002/alz.12727.
    >> Share

  37. TIAN C, Stewart T, Hong Z, Guo Z, et al
    Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease.
    Alzheimers Dement. 2022 Jul 2. doi: 10.1002/alz.12723.
    >> Share

  38. SALVADO G, Ferreira D, Operto G, Cumplido-Mayoral I, et al
    The protective gene dose effect of the APOE epsilon2 allele on gray matter volume in cognitively unimpaired individuals.
    Alzheimers Dement. 2022;18:1383-1395.
    >> Share

  39. KATSEL P, Fam P, Tan W, Khan S, et al
    Engagement of vascular early response genes typifies mild cognitive impairment.
    Alzheimers Dement. 2022;18:1357-1369.
    >> Share

    June 2022
  40. CHUNG J, Das A, Sun X, Sobreira DR, et al
    Genome-wide association and multi-omics studies identify MGMT as a novel risk gene for Alzheimer's disease among women.
    Alzheimers Dement. 2022 Jun 30. doi: 10.1002/alz.12719.
    >> Share

  41. WEINER MW, Harvey D, Landau SM, Veitch DP, et al
    Traumatic brain injury and post-traumatic stress disorder are not associated with Alzheimer's disease pathology measured with biomarkers.
    Alzheimers Dement. 2022 Jun 29. doi: 10.1002/alz.12712.
    >> Share

  42. ABDULRAHMAN H, van Dalen JW, den Brok M, Latimer CS, et al
    Hypertension and Alzheimer's disease pathology at autopsy: A systematic review.
    Alzheimers Dement. 2022 Jun 27. doi: 10.1002/alz.12707.
    >> Share

  43. WINGO TS, Gerasimov ES, Canon SM, Lah JJ, et al
    Alzheimer's disease genetic burden is associated with mid-life depression among persons with normal cognition.
    Alzheimers Dement. 2022 Jun 21. doi: 10.1002/alz.12716.
    >> Share

  44. CULLEN NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12706.
    >> Share

  45. DELVENNE A, Gobom J, Tijms B, Bos I, et al
    Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12713.
    >> Share

  46. SINGH NA, Tosakulwong N, Graff-Radford J, Machulda MM, et al
    APOE epsilon4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease.
    Alzheimers Dement. 2022 Jun 12. doi: 10.1002/alz.12711.
    >> Share

  47. RISCHEL EB, Gejl M, Brock B, Rungby J, et al
    In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails.
    Alzheimers Dement. 2022 Jun 8. doi: 10.1002/alz.12701.
    >> Share

  48. GAO F, Lv X, Dai L, Wang Q, et al
    A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study.
    Alzheimers Dement. 2022 Jun 6. doi: 10.1002/alz.12700.
    >> Share

  49. GUSTAVSSON A, Norton N, Fast T, Frolich L, et al
    Global estimates on the number of persons across the Alzheimer's disease continuum.
    Alzheimers Dement. 2022 Jun 2. doi: 10.1002/alz.12694.
    >> Share

  50. SAWA M, Overk C, Becker A, Derse D, et al
    Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.
    Alzheimers Dement. 2022;18:1203-1234.
    >> Share

  51. SYRJANEN JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, et al
    Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
    Alzheimers Dement. 2022;18:1128-1140.
    >> Share

  52. LIU L, Kwak H, Lawton TL, Jin SX, et al
    An ultra-sensitive immunoassay detects and quantifies soluble Abeta oligomers in human plasma.
    Alzheimers Dement. 2022;18:1186-1202.
    >> Share

  53. SANZ-BLASCO R, Ruiz-Sanchez de Leon JM, Avila-Villanueva M, Valenti-Soler M, et al
    Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models.
    Alzheimers Dement. 2022;18:1177-1185.
    >> Share

    May 2022
  54. VOGLEIN J, Franzmeier N, Morris JC, Dieterich M, et al
    Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 May 24. doi: 10.1002/alz.12684.
    >> Share

  55. HU Y, Zhang Y, Zhang H, Gao S, et al
    Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk.
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12687.
    >> Share

  56. LUO J, Thomassen JQ, Hegazy SH, Rasmussen IJ, et al
    Reply to "Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk".
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12688.
    >> Share

  57. ASHLEIGH T, Swerdlow RH, Beal MF
    The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis.
    Alzheimers Dement. 2022 May 6. doi: 10.1002/alz.12683.
    >> Share

  58. SEXTON C, Snyder H, Beher D, Boxer AL, et al
    Current directions in tau research: Highlights from Tau 2020.
    Alzheimers Dement. 2022;18:988-1007.
    >> Share

  59. IMBIMBO BP, Ippati S, Watling M, Balducci C, et al
    A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.
    Alzheimers Dement. 2022;18:1008-1037.
    >> Share

  60. PERRY BL, McConnell WR, Coleman ME, Roth AR, et al
    Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness.
    Alzheimers Dement. 2022;18:934-941.
    >> Share

    April 2022
  61. CHANG R, Trushina E, Zhu K, Zaidi SSA, et al
    Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 28. doi: 10.1002/alz.12675.
    >> Share

  62. PARK SY, Setiawan VW, White LR, Wu AH, et al
    Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Apr 27. doi: 10.1002/alz.12677.
    >> Share

  63. JESSEN F, Wolfsgruber S, Kleineindam L, Spottke A, et al
    Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.
    Alzheimers Dement. 2022 Apr 22. doi: 10.1002/alz.12674.
    >> Share

  64. QUAN L, Moreno-Gonzalez I, Xie Z, Gamez N, et al
    A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 18. doi: 10.1002/alz.12673.
    >> Share

  65. TJANDRA D, Migrino RQ, Giordani B, Wiens J, et al
    Use of blood pressure measurements extracted from the electronic health record in predicting Alzheimer's disease: A retrospective cohort study at two medical centers.
    Alzheimers Dement. 2022 Apr 16. doi: 10.1002/alz.12676.
    >> Share

  66. TA PARK VM, Meyer OL, Tsoh JY, Kanaya AM, et al
    The Collaborative Approach for Asian Americans and Pacific Islanders Research and Education (CARE): A recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver-related research.
    Alzheimers Dement. 2022 Apr 14. doi: 10.1002/alz.12667.
    >> Share

  67. MARTINEZ AE, Weissberger G, Kuklenyik Z, He X, et al
    The small HDL particle hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 13. doi: 10.1002/alz.12649.
    >> Share

  68. MIELKE MM, Aggarwal NT, Vila-Castelar C, Agarwal P, et al
    Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.
    Alzheimers Dement. 2022 Apr 8. doi: 10.1002/alz.12662.
    >> Share

  69. WANG Y, Li M, Kazis LE, Xia W, et al
    Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.
    Alzheimers Dement. 2022 Apr 4. doi: 10.1002/alz.12665.
    >> Share

  70. LUCKETT PH, Chen C, Gordon BA, Wisch J, et al
    Biomarker clustering in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 1. doi: 10.1002/alz.12661.
    >> Share

  71. NEUPANE A, Lenny B, Budde JP, Wang F, et al
    Replication study of AD-associated rare variants.
    Alzheimers Dement. 2022;18:858-862.
    >> Share

  72. AKINYEMI RO, Yaria J, Ojagbemi A, Guerchet M, et al
    Dementia in Africa: Current evidence, knowledge gaps, and future directions.
    Alzheimers Dement. 2022;18:790-809.
    >> Share

  73. MURA T, Coley N, Amieva H, Berr C, et al
    Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
    Alzheimers Dement. 2022;18:676-687.
    >> Share

  74. LINDBOHM JV, Mars N, Walker KA, Singh-Manoux A, et al
    Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.
    Alzheimers Dement. 2022;18:612-624.
    >> Share

  75. POURHADI N, Morch LS, Holm EA, Torp-Pedersen CT, et al
    Vaginal estrogen and association with dementia: A nationwide population-based study.
    Alzheimers Dement. 2022;18:625-634.
    >> Share

  76. MIELKE MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, et al
    Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.
    Alzheimers Dement. 2022;18:602-611.
    >> Share

  77. CASANOVA R, Hsu FC, Barnard RT, Anderson AM, et al
    Comparing data-driven and hypothesis-driven MRI-based predictors of cognitive impairment in individuals from the Atherosclerosis Risk in Communities (ARIC) study.
    Alzheimers Dement. 2022;18:561-571.
    >> Share

  78. YANG HS, Zhang C, Carlyle BC, Zhen SY, et al
    Plasma IL-12/IFN-gamma axis predicts cognitive trajectories in cognitively unimpaired older adults.
    Alzheimers Dement. 2022;18:645-653.
    >> Share

    March 2022
  79. BRODY M, Agronin M, Herskowitz BJ, Bookheimer SY, et al
    Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 31. doi: 10.1002/alz.12651.
    >> Share

  80. ZHANG X, Tong T, Chang A, Ang TFA, et al
    Midlife lipid and glucose levels are associated with Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 23. doi: 10.1002/alz.12641.
    >> Share

  81. JACOBS HIL, Becker JA, Kwong K, Munera D, et al
    Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12656.
    >> Share

  82. LI P, Gao L, Yu L, Zheng X, et al
    Daytime napping and Alzheimer's dementia: A potential bidirectional relationship.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12636.
    >> Share

  83. COE NB, White L, Oney M, Basu A, et al
    Public spending on acute and long-term care for Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Mar 16. doi: 10.1002/alz.12657.
    >> Share


  84. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2022 Mar 14. doi: 10.1002/alz.12638.
    >> Share

  85. LIU L, Lauro BM, He A, Lee H, et al
    Identification of the Abeta37/42 peptide ratio in CSF as an improved Abeta biomarker for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 12. doi: 10.1002/alz.12646.
    >> Share

  86. WINDER Z, Sudduth TL, Anderson S, Patel E, et al
    Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.
    Alzheimers Dement. 2022 Mar 10. doi: 10.1002/alz.12639.
    >> Share

  87. BREITNER JCS, Dodge HH, Khachaturian ZS, Khachaturian AS, et al
    "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12633.
    >> Share


  88. Alzheimer's Association welcomes new Medical and Scientific Advisory Group members.
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12621.
    >> Share

  89. O'BRYANT SE, Petersen M, Hall J, Johnson LA, et al
    Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12647.
    >> Share

  90. CONNOLLY K, Lehoux M, O'Rourke R, Assetta B, et al
    Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12612.
    >> Share

  91. STOCKER H, Beyer L, Perna L, Rujescu D, et al
    Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12614.
    >> Share

  92. CUMMINGS J, Salloway S
    Aducanumab: Appropriate use recommendations.
    Alzheimers Dement. 2022;18:531-533.
    >> Share

  93. PETERSON A, Clapp J, Largent EA, Harkins K, et al
    What is paradoxical lucidity? The answer begins with its definition.
    Alzheimers Dement. 2022;18:513-521.
    >> Share

  94. BARIL AA, Beiser AS, Sanchez E, Mysliwiec V, et al
    Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype.
    Alzheimers Dement. 2022;18:408-421.
    >> Share

    February 2022
  95. GIETL AF, Frisoni GB
    Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
    Alzheimers Dement. 2022 Feb 27. doi: 10.1002/alz.12605.
    >> Share

  96. KETCHUM FB, Chin NA, Grill J, Gleason CE, et al
    Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12620.
    >> Share

  97. ASHFORD MT, Raman R, Miller G, Donohue MC, et al
    Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12640.
    >> Share

  98. ZETTERBERG H
    Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12618.
    >> Share

  99. XIONG C, Luo J, Schindler SE, Fagan AM, et al
    Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12608.
    >> Share

  100. MONI F, Petersen ME, Zhang F, Lao PJ, et al
    Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12627.
    >> Share

  101. LEVIN J, Voglein J, Quiroz YT, Bateman RJ, et al
    Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12624.
    >> Share

  102. QUIROZ YT, Solis M, Aranda MP, Arbaje AI, et al
    Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12589.
    >> Share

  103. SEXTON C, Solis M, Aharon-Peretz J, Alexopoulos P, et al
    Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium.
    Alzheimers Dement. 2022 Feb 20. doi: 10.1002/alz.12588.
    >> Share

  104. MECCA AP, O'Dell RS, Sharp ES, Banks ER, et al
    Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11) C]UCB-J.
    Alzheimers Dement. 2022 Feb 17. doi: 10.1002/alz.12582.
    >> Share

  105. SUCHY-DICEY A, Howard B, Longstreth WT Jr, Reiman EM, et al
    APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.
    Alzheimers Dement. 2022 Feb 10. doi: 10.1002/alz.12573.
    >> Share

  106. KRELL-ROESCH J, Rakusa M, Syrjanen JA, van Harten AC, et al
    Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12557.
    >> Share

  107. CLAES C, England WE, Danhash EP, Kiani Shabestari S, et al
    The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12577.
    >> Share

  108. HU WT
    Reporting and social construction of race in Alzheimer's disease clinical trials.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12609.
    >> Share

  109. ASTILLERO-LOPEZ V, Gonzalez-Rodriguez M, Villar-Conde S, Flores-Cuadrado A, et al
    Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer-specific assessment and proteomic analysis.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12580.
    >> Share

  110. FLACH M, Leu C, Martinisi A, Skachokova Z, et al
    Trans-seeding of Alzheimer-related tau protein by a yeast prion.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12581.
    >> Share

  111. PRADOS MJ, Liu Y, Jun H, Lam J, et al
    Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12578.
    >> Share

  112. BABULAL GM, Franzen S, Abner EL, Smith JE, et al
    Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12611.
    >> Share

  113. JUN GR, You Y, Zhu C, Meng G, et al
    Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE varepsilon2 for Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12607.
    >> Share

  114. VARDARAJAN BN, Reyes-Dumeyer D, Piriz AL, Lantigua RA, et al
    Progranulin mutations in clinical and neuropathological Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12567.
    >> Share

  115. REIKEN S, Sittenfeld L, Dridi H, Liu Y, et al
    Alzheimer's-like signaling in brains of COVID-19 patients.
    Alzheimers Dement. 2022 Feb 3. doi: 10.1002/alz.12558.
    >> Share

  116. RUTHIRAKUHAN M, Ismail Z, Herrmann N, Gallagher D, et al
    Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12519.
    >> Share

  117. REIMAN EM, Mattke S, Kordower JH, Khachaturian ZS, et al
    Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12533.
    >> Share


  118. Applications being accepted for the Alzheimer's Association Interdisciplinary Summer Research Institute.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12585.
    >> Share

  119. VILA-CASTELAR C, Tariot PN, Sink KM, Clayton D, et al
    Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12552.
    >> Share

  120. WAGNER M, Wilson RS, Leurgans SE, Boyle PA, et al
    Quantifying longitudinal cognitive resilience to Alzheimer's disease and other neuropathologies.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12576.
    >> Share

  121. ERATNE D, Loi SM, Li QX, Stehmann C, et al
    Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12549.
    >> Share

  122. O'BRYANT S, Petersen M, Hall J, Johnson L, et al
    Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.
    Alzheimers Dement. 2022;18:240-250.
    >> Share

  123. NAUEN DW, Troncoso JC
    Amyloid-beta is present in human lymph nodes and greatly enriched in those of the cervical region.
    Alzheimers Dement. 2022;18:205-210.
    >> Share

  124. KREISL WC, Lao PJ, Johnson A, Tomljanovic Z, et al
    Patterns of tau pathology identified with (18) F-MK-6240 PET imaging.
    Alzheimers Dement. 2022;18:272-282.
    >> Share

  125. SCHMUTTE T, Olfson M, Maust DT, Xie M, et al
    Suicide risk in first year after dementia diagnosis in older adults.
    Alzheimers Dement. 2022;18:262-271.
    >> Share

    January 2022
  126. CALDWELL AB, Liu Q, Zhang C, Schroth GP, et al
    Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 27. doi: 10.1002/alz.12553.
    >> Share

  127. WANG T, Huynh K, Giles C, Mellett NA, et al
    APOE epsilon2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12538.
    >> Share

  128. JORDA-SIQUIER T, Petrel M, Kouskoff V, Smailovic U, et al
    APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12546.
    >> Share

  129. FRONTERA JA, Boutajangout A, Masurkar AV, Betensky RA, et al
    Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
    Alzheimers Dement. 2022 Jan 13. doi: 10.1002/alz.12556.
    >> Share

  130. YAO J, Liu Y, Sun B, Zhan X, et al
    Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer's disease-causing gene mutations.
    Alzheimers Dement. 2022 Jan 5. doi: 10.1002/alz.12543.
    >> Share

  131. NAZARIAN A, Loika Y, He L, Culminskaya I, et al
    Genome-wide analysis identified abundant genetic modulators of contributions of the apolipoprotein E alleles to Alzheimer's disease risk.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12540.
    >> Share

  132. REYES-DUMEYER D, Faber K, Vardarajan B, Goate A, et al
    The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12514.
    >> Share

  133. QIU S, Hu Y, Cheng L
    BIN1 rs744373 located in enhancers of brain tissues upregulates BIN1 mRNA expression, thereby leading to Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12548.
    >> Share

  134. ZAMOLODCHIKOV D, Duffield M, Macdonald LE, Alessandri-Haber N, et al
    Accumulation of high molecular weight kininogen in the brains of Alzheimer's disease patients may affect microglial function by altering phagocytosis and lysosomal cathepsin activity.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12531.
    >> Share


  135. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor-in-chief for open access, peer reviewed journal.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12517.
    >> Share

  136. KETCHUM FB
    Solomon Carter Fuller: Alzheimer's contemporary and American pioneer.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12551.
    >> Share

  137. JAKEL L, De Kort AM, Klijn CJM, Schreuder FHBM, et al
    Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.
    Alzheimers Dement. 2022;18:10-28.
    >> Share

  138. ZHAO Y, Kuca K, Wu W, Wang X, et al
    Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases.
    Alzheimers Dement. 2022;18:152-158.
    >> Share

  139. BUTT OH, Meeker KL, Wisch JK, Schindler SE, et al
    Network dysfunction in cognitively normal APOE epsilon4 carriers is related to subclinical tau.
    Alzheimers Dement. 2022;18:116-126.
    >> Share

  140. VOGT NM, Hunt JFV, Adluru N, Ma Y, et al
    Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.
    Alzheimers Dement. 2022;18:65-76.
    >> Share

    December 2021
  141. DELABY C, Teunissen CE, Blennow K, Alcolea D, et al
    Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.
    Alzheimers Dement. 2021 Dec 22. doi: 10.1002/alz.12545.
    >> Share

  142. MING C, Wang M, Wang Q, Neff R, et al
    Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 17. doi: 10.1002/alz.12507.
    >> Share

  143. HAWKINSON TR, Clarke HA, Young LEA, Conroy LR, et al
    In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains.
    Alzheimers Dement. 2021 Dec 15. doi: 10.1002/alz.12523.
    >> Share

  144. LIM U, Wang S, Park SY, Bogumil D, et al
    Risk of Alzheimer's disease and related dementia by sex and race/ethnicity: The Multiethnic Cohort Study.
    Alzheimers Dement. 2021 Dec 9. doi: 10.1002/alz.12528.
    >> Share

  145. GORDON MN, Heneka MT, Le Page LM, Limberger C, et al
    Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12488.
    >> Share

  146. DE KORT AM, Kuiperij HB, Kersten I, Versleijen AAM, et al
    Normal cerebrospinal fluid concentrations of PDGFRbeta in patients with cerebral amyloid angiopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12506.
    >> Share

  147. SILVERMAN W, Krinsky-McHale SJ, Zigman WB, Schupf N, et al
    Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12520.
    >> Share

  148. SAROJA SR, Sharma A, Hof PR, Pereira AC, et al
    Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12518.
    >> Share

  149. GLEASON CE, Zuelsdorff M, Gooding DC, Kind AJH, et al
    Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.
    Alzheimers Dement. 2021 Dec 6. doi: 10.1002/alz.12511.
    >> Share

  150. HAEGER A, Bottlaender M, Lagarde J, Porciuncula Baptista R, et al
    What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12501.
    >> Share


  151. AAIC 2021: The promise of Alzheimer's research.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12500.
    >> Share

  152. FRANK B, Ally M, Brekke B, Zetterberg H, et al
    Plasma p-tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12508.
    >> Share

  153. STATHAS S, Alvarez VE, Xia W, Nicks R, et al
    Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12502.
    >> Share

  154. BUCKLES VD, Xiong C, Bateman RJ, Hassenstab J, et al
    Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12505.
    >> Share

  155. STRINGER C, Smithroat N, Samus QM, Johnston D, et al
    From research to realization: How a Texas health plan implemented an academic model of care for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054058.
    >> Share

  156. MENENGIC KN, Yeldan I, Cinar N, Sahiner TA, et al
    Effectiveness of home-based telerehabilitation in mild to moderate Alzheimer's disease: A randomised controlled study.
    Alzheimers Dement. 2021;17 Suppl 8:e053406.
    >> Share

  157. ASCHETTINO LA, Labyak CA, Sealey-Potts C
    Nutritional treatments for Alzheimer's disease: A narrative review.
    Alzheimers Dement. 2021;17 Suppl 8:e053172.
    >> Share

  158. LEE JH, Kim DY, Kim MG, Kang H, et al
    Preventing cognitive decline in older adults with mild cognitive impairment using integrated Korean and Western treatments: Initial results.
    Alzheimers Dement. 2021;17 Suppl 8:e052545.
    >> Share

  159. GELDMACHER DS, Christopher R, Anderson M, Bero AW, et al
    Development of a site readiness framework to improve health system preparedness for potential new Alzheimer's disease therapies.
    Alzheimers Dement. 2021;17 Suppl 8:e057672.
    >> Share

  160. KEELY AJ
    The first female engineer at General Motor's descent into Alzheimer's with sundowners: A daughter's scholarly research and case study as caregiver.
    Alzheimers Dement. 2021;17 Suppl 8:e050143.
    >> Share

  161. FLATT JD, Pollock K, Lee R, Song Y, et al
    Feasibility of the Savvy Caregiver program for care providers of LGBTQ adults living with Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021;17 Suppl 8:e055633.
    >> Share

  162. MILLER DR, Jasuja G, Davila HW, Palnati M, et al
    Care processes related to clinical detection of Alzheimer's disease in the U.S. Veterans Affairs Health Care System.
    Alzheimers Dement. 2021;17 Suppl 8:e054149.
    >> Share

  163. MAKSIMOVICH IV
    Stimulation of cerebral angiogenesis and neurogenesis with transcatheter intracerebral laser photobiomodulation therapy during dementia in patients with Alzheimer's and Binswanger's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054945.
    >> Share

  164. GONZALEZ A, Camila C, Maccioni RB
    Alzheimer's disease: A potential diabetes type 3.
    Alzheimers Dement. 2021;17 Suppl 2:e058533.
    >> Share

  165. MOYLAN C, Cao TV, Huynh QS, Pratap A, et al
    Exercise-Induced Alterations in TrkB expression in the 5XFAD Mouse Model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058733.
    >> Share

  166. GAITAN JM, Dubal DB, Okonkwo OC
    Circulating klotho is elevated in cerebrospinal fluid, but not serum, among KLOTHO KL-VS allele carriers at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058612.
    >> Share

  167. COULON A, Mendes T, Kilinc D, Dumont J, et al
    High-content screening of Alzheimer's disease genetic risk factors based on synaptic density analysis.
    Alzheimers Dement. 2021;17 Suppl 2:e058660.
    >> Share

  168. TSAI AP, Lin PB, Dong C, Moutinho M, et al
    Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058740.
    >> Share

  169. HUANG CW, Hart GW
    Decreased O-GlcNAcylation and mitochondrial dysfunction are involving in low glucose induced Alzheimer's disease-like phenotype in induced pluripotent stem cell-derived neurons.
    Alzheimers Dement. 2021;17 Suppl 2:e058620.
    >> Share

  170. BRACH TL, Gaitan JM, Okonkwo OC
    Effect of Aerobic Exercise Training on Mood and Cognition in Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058523.
    >> Share

  171. LIN PB, Tsai AP, Nho K, Lamb BT, et al
    INPP5D regulates the amyloid pathology in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058724.
    >> Share

  172. KUMAR A, Doran E, Martini AC, Head E, et al
    CAA and related co-morbidities in Down syndrome and Alzheimer disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058726.
    >> Share

  173. TEMITOPE SR
    The role of lycopene on the hippocampus of rat model of lipopolysaccharide-induced Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058528.
    >> Share

  174. YEATES C, Sarkar A, Deshpande P, Kango-Singh M, et al
    A Two-Clone approach to study signaling interactions among neuronal cells in a pre-clinical Alzheimer's Disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058690.
    >> Share

  175. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Colocalization of the beta amyloid peptide with bacteria in postmortem brain tissue of patients with familial Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058692.
    >> Share

  176. SUNG K, Yang F, Noble W, Jimenez-Sanchez M, et al
    Investigating the non-cell autonomous role of glial chaperones in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058572.
    >> Share

  177. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Human Herpesvirus detection and identification in postmortem brain tissue of patients with Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058693.
    >> Share

  178. SCHRAUBEN M, Smith AR, Washer S, Dempster E, et al
    Investigating epigenetic loci implicated in Alzheimer's disease via the CRISPR-Cas9 system.
    Alzheimers Dement. 2021;17 Suppl 2:e058573.
    >> Share

  179. TALIYAN R, Kakoty V, Kc S, Kumari S, et al
    Fibroblast Growth Factor 21 and Autophagy Modulation Ameliorates Amyloid beta-Induced Alzheimer Disease Pathology in Rats.
    Alzheimers Dement. 2021;17 Suppl 2:e058695.
    >> Share

  180. YANG F, Sung K, Sanchez MJ
    Investigating the secretion of small heat shock proteins in reactive astrocytes in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058498.
    >> Share

  181. ROSENE MJ, Hsu S, Martinez R, Norton J, et al
    Defining the role of PLD3 in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 2:e058730.
    >> Share

  182. TREMBLAY JP, Tremblay G, Guyon A, Joel R, et al
    Insertion of the Icelandic mutation (A673T) in the APP gene using the CRISPR/Cas9 base editing and Prime editing technologies, a preventive treatment for Alzheimer?
    Alzheimers Dement. 2021;17 Suppl 2:e058710.
    >> Share

  183. CHEN J, Samoylova NG, Cummings MG
    TOMM40, a risk gene for Alzheimer's disease, is upregulated during proinflammatory response.
    Alzheimers Dement. 2021;17 Suppl 2:e058711.
    >> Share

  184. MCARDLE CJ, Niere F, Uneri A, Raab-Graham KF, et al
    Alterations in dendritic GABAB receptor expression in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2021;17 Suppl 2:e058557.
    >> Share

  185. DESHPANDE P, Chen CY, Yeates C, Chen CH, et al
    miR-277 targets hid to ameliorate Abeta42-mediated neurodegeneration in Drosophila eye model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058678.
    >> Share

  186. ZHAO P, Mangleburg CG, Al-Ramahi I, Botas J, et al
    Systems genetic dissection of Alzheimer's disease brain gene expression networks.
    Alzheimers Dement. 2021;17 Suppl 2:e058716.
    >> Share

  187. MUMFORD P, Noy S, Tybulewicz VL, Fisher E, et al
    Preclinical modelling in the mouse of altered neuroinflammation in Alzheimer's disease - Down syndrome.
    Alzheimers Dement. 2021;17 Suppl 2:e058441.
    >> Share

  188. TIPTON AE, George J, Ratner M, Farb D, et al
    Data from single nuclei RNA-sequencing reveals a prodromal gene network response in excitatory neurons of a humanized rat Alzheimer's disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058589.
    >> Share

  189. TAYLOR AL, Davis DE Jr, Codreanu SG, Harrison FE, et al
    Targeted and untargeted mass spectrometry reveals impact of high fat diet on peripheral amino acid regulation in a mouse model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058428.
    >> Share

  190. ROSOLEN SA
    Exercise-induced metabolic changes in astrocytes in the 5xFAD mouse model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058627.
    >> Share

  191. SRIVASTAV A, Mohideen SS
    Intestinal microbial dysbiosis induced tau accumulation establishes a gut-brain correlation for pathology Alzheimer's disease in Drosophila melanogaster.
    Alzheimers Dement. 2021;17 Suppl 2:e058708.
    >> Share

  192. HERSH SW, You Y, Aslebagh R, Shaffer SA, et al
    Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells.
    Alzheimers Dement. 2021;17 Suppl 2:e058592.
    >> Share

  193. PRATER KE, Green KJ, Chiou KL, Smith CL, et al
    Microglia subtype transcriptomes differ between Alzheimer Disease and control human postmortem brain samples.
    Alzheimers Dement. 2021;17 Suppl 2:e058474.
    >> Share

  194. CZAPLICKI AM, Gaitan JM, Bendlin BB, Johnson SC, et al
    The Interaction between Ventricle to Brain Ratio and Serum Klotho on Cognition in Older Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058632.
    >> Share

  195. BABATOPE EY, Acosta-Franco JA, Garcia-Vazquez MS, Ramirez-Acosta AA, et al
    Applying a deep learning approach focusing on spatiotemporal features in early diagnosis of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058635.
    >> Share

  196. MCINTYRE CC, Okonkwo OC, Gaitan JM, Bendlin BB, et al
    Effect of insulin resistance on the association between cardiorespiratory fitness and cognition in adults at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058683.
    >> Share

  197. WANG RP, Leung WK, Goto T, Ho JY, et al
    IL-1 beta and TNF-alpha play an essential role in modulating the risk of both periodontitis and Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058464.
    >> Share

  198. MEMUDU AE, Waziri RJ
    An investigative study to demonstrate the link between combined intake of marijuana and codeine in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 12:e058465.
    >> Share

  199. RISHITHA N, Muthuraman A
    Therapeutic investigation of alpha napthoflavone in the intracerebroventricular injection of L-cysteine induced vascular dementia in rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058344.
    >> Share

  200. ABDULKADIR TS, Isa AS, Dawud FA, Ayo JO, et al
    Effect of taurine and camel milk on amyloid beta peptide concentration and oxidative stress changes in aluminium chloride-induced Alzheimer's disease rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058642.
    >> Share

  201. OKHUEVBIE DO, Awolaja S, Balogun Z
    Evaluation of the effect of Donepezil hydrochloride on Ethanol-induced hippocampal damage.
    Alzheimers Dement. 2021;17 Suppl 12:e058353.
    >> Share

  202. K C S, Kakoty VK, Taliyan R
    Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058674.
    >> Share

  203. TORT-MERINO A, Tarnanas I, Bugler M, Harms R, et al
    ALTOIDA-iADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e057982.
    >> Share

  204. ROWE EM, Louadi S, Koch E, Kuhlmann N, et al
    A Month in Neurodegenerative Disease Research (AMiNDR): The evolution of an open-access podcast series for Alzheimer's researchers.
    Alzheimers Dement. 2021;17 Suppl 11:e053287.
    >> Share

  205. YUAN F, Lopez RP, Crane M, Montgomery A, et al
    Feasibility and acceptance of robotic care of Alzheimer's disease and related dementia.
    Alzheimers Dement. 2021;17 Suppl 11:e052585.
    >> Share

  206. KUHNEL L, Bouteloup V, Lespinasse J, Chene G, et al
    Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study.
    Alzheimers Dement. 2021;17:1938-1949.
    >> Share

  207. GOLD BT, Shao X, Sudduth TL, Jicha GA, et al
    Water exchange rate across the blood-brain barrier is associated with CSF amyloid-beta 42 in healthy older adults.
    Alzheimers Dement. 2021;17:2020-2029.
    >> Share

  208. XU Y, Chen Z, Wey HY, Liang Y, et al
    Molecular imaging of NAD(+) -dependent deacetylase SIRT1 in the brain.
    Alzheimers Dement. 2021;17:1988-1997.
    >> Share

    November 2021
  209. VERBERK IMW, Misdorp EO, Koelewijn J, Ball AJ, et al
    Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.
    Alzheimers Dement. 2021 Nov 29. doi: 10.1002/alz.12510.
    >> Share

  210. MURCHISON AG
    Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12503.
    >> Share

  211. JIA L, Yang J, Zhu M, Pang Y, et al
    A metabolite panel that differentiates Alzheimer's disease from other dementia types.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12484.
    >> Share

  212. WEINTRAUB S, Karpouzian-Rogers T, Peipert JD, Nowinski C, et al
    ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12497.
    >> Share

  213. JUTKOWITZ E, Halladay C, Tsai J, Hooshyar D, et al
    Prevalence of Alzheimer's disease and related dementias among veterans experiencing housing insecurity.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12476.
    >> Share

  214. HORGUSLUOGLU E, Neff R, Song WM, Wang M, et al
    Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12468.
    >> Share

  215. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Alzheimers Dement. 2021 Nov 2. doi: 10.1002/alz.12477.
    >> Share

  216. EZZATI A, Abdulkadir A, Jack CR Jr, Thompson PM, et al
    Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia.
    Alzheimers Dement. 2021;17:1855-1867.
    >> Share

  217. TAHIRA AC, Verjovski-Almeida S, Ferreira ST
    Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.
    Alzheimers Dement. 2021;17:1818-1831.
    >> Share

    October 2021
  218. TOSUN D, Demir Z, Veitch DP, Weintraub D, et al
    Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Alzheimers Dement. 2021 Oct 14. doi: 10.1002/alz.12480.
    >> Share

  219. MEYERS EA, Amouyel P, Bovenkamp DE, Carrillo MC, et al
    Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic.
    Alzheimers Dement. 2021 Oct 1. doi: 10.1002/alz.12472.
    >> Share


  220. Alzheimer's Disease Interventions: Implications of therapeutic promises amidst questions and doubts about clinically meaningful outcomes.
    Alzheimers Dement. 2021;17:1591-1594.
    >> Share

  221. DE MAULEON A, Ismail Z, Rosenberg P, Miller D, et al
    Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    Alzheimers Dement. 2021;17:1687-1697.
    >> Share

  222. DAMOTTE V, van der Lee SJ, Chouraki V, Grenier-Boley B, et al
    Plasma amyloid beta levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.
    Alzheimers Dement. 2021;17:1663-1674.
    >> Share

  223. BANGEN KJ, Thomas KR, Weigand AJ, Edmonds EC, et al
    Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.
    Alzheimers Dement. 2021;17:1756-1762.
    >> Share

  224. MEZ J, Alosco ML, Daneshvar DH, Saltiel N, et al
    Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology.
    Alzheimers Dement. 2021;17:1709-1724.
    >> Share

  225. GALVIN JE, Chrisphonte S, Cohen I, Greenfield KK, et al
    Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD-MOD).
    Alzheimers Dement. 2021;17:1675-1686.
    >> Share

  226. YANG C, Li X, Zhang J, Chen Y, et al
    Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative.
    Alzheimers Dement. 2021;17:1610-1618.
    >> Share

    September 2021
  227. FRANZEN S, Smith JE, van den Berg E, Rivera Mindt M, et al
    Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
    Alzheimers Dement. 2021 Sep 30. doi: 10.1002/alz.12433.
    >> Share

  228. PICARD C, Nilsson N, Labonte A, Auld D, et al
    Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12442.
    >> Share

  229. JICHA GA, Abner EL, Arnold SE, Carrillo MC, et al
    Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12461.
    >> Share

  230. CUMMINGS JL, Goldman DP, Simmons-Stern NR, Ponton E, et al
    The costs of developing treatments for Alzheimer's disease: A retrospective exploration.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12450.
    >> Share

  231. VEITCH DP, Weiner MW, Aisen PS, Beckett LA, et al
    Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12422.
    >> Share

  232. WANG C, Wang Z, Xie B, Shi X, et al
    Binaural processing deficit and cognitive impairment in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12464.
    >> Share

  233. MATTKE S, Hanson M
    Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12470.
    >> Share

  234. PHILLIPS JS, Nitchie FJ 4th, Da Re F, Olm CA, et al
    Rates of longitudinal change in (18) F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 13. doi: 10.1002/alz.12456.
    >> Share

  235. ZHANG L, Du Rietz E, Kuja-Halkola R, Dobrosavljevic M, et al
    Attention-deficit/hyperactivity disorder and Alzheimer's disease and any dementia: A multi-generation cohort study in Sweden.
    Alzheimers Dement. 2021 Sep 9. doi: 10.1002/alz.12462.
    >> Share

  236. CHATTERJEE P, Pedrini S, Ashton NJ, Tegg M, et al
    Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12447.
    >> Share

  237. MARTERSTECK A, Sridhar J, Coventry C, Weintraub S, et al
    Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12445.
    >> Share

  238. LOGSDON AF, Francis KL, Richardson NE, Hu SJ, et al
    Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12451.
    >> Share

  239. MA Y, Yu L, Olah M, Smith R, et al
    Epigenomic features related to microglia are associated with attenuated effect of APOE epsilon4 on Alzheimer's disease risk in humans.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12425.
    >> Share

  240. REN RJ, Huang Q, Xu G, Gu K, et al
    Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12436.
    >> Share

  241. PEGUEROLES J, Montal V, Bejanin A, Vilaplana E, et al
    AMYQ: An index to standardize quantitative amyloid load across PET tracers.
    Alzheimers Dement. 2021;17:1499-1508.
    >> Share

    August 2021
  242. GHAZARIAN AL, Haim T, Sauma S, Katiyar P, et al
    National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
    Alzheimers Dement. 2021 Aug 10. doi: 10.1002/alz.12392.
    >> Share

  243. WANG Q, Davis PB, Gurney ME, Xu R, et al
    COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US.
    Alzheimers Dement. 2021;17:1297-1306.
    >> Share

  244. PIERUCCINI-FARIA F, Black SE, Masellis M, Smith EE, et al
    Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.
    Alzheimers Dement. 2021;17:1317-1328.
    >> Share

  245. BAUCKNEHT M, Chincarini A, Brendel M, Rominger A, et al
    Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project.
    Alzheimers Dement. 2021;17:1277-1286.
    >> Share

  246. GIANATTASIO KZ, Bennett EE, Wei J, Mehrotra ML, et al
    Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC.
    Alzheimers Dement. 2021;17:1265-1276.
    >> Share

    July 2021
  247. GARNIER-CRUSSARD A, Bougacha S, Wirth M, Dautricourt S, et al
    White matter hyperintensity topography in Alzheimer's disease and links to cognition.
    Alzheimers Dement. 2021 Jul 28. doi: 10.1002/alz.12410.
    >> Share

  248. BOADA M, Rodrigo A, Jessen F, Wimblad B, et al
    Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12441.
    >> Share

  249. HOSCHEIDT S, Sanderlin AH, Baker LD, Jung Y, et al
    Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12421.
    >> Share

  250. VAN HARTEN AC, Wiste HJ, Weigand SD, Mielke MM, et al
    Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12406.
    >> Share

  251. KULMINSKI AM, Philipp I, Loika Y, He L, et al
    Protective association of the epsilon2/epsilon3 heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12413.
    >> Share

  252. BOCHE D, Gordon MN
    Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease.
    Alzheimers Dement. 2021 Jul 5. doi: 10.1002/alz.12389.
    >> Share

  253. BAO H, Liu Y, Zhang M, Chen Z, et al
    Increased beta-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment.
    Alzheimers Dement. 2021;17:1097-1108.
    >> Share

    June 2021
  254. ZHANG X, Farrell JJ, Tong T, Hu J, et al
    Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12396.
    >> Share

  255. TEERLINK CC, Miller JB, Vance EL, Staley LA, et al
    Analysis of high-risk pedigrees identifies 12 candidate variants for Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12397.
    >> Share

  256. ZHONG W, Wu A, Berglund K, Gu X, et al
    Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12398.
    >> Share

  257. JANELIDZE S, Palmqvist S, Leuzy A, Stomrud E, et al
    Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p-tau.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395.
    >> Share

  258. BIRKENBIHL C, Salimi Y, Frohlich H
    Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling.
    Alzheimers Dement. 2021 Jun 9. doi: 10.1002/alz.12387.
    >> Share

  259. LOPEZ-RODRIGUEZ AB, Hennessy E, Murray CL, Nazmi A, et al
    Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1beta drives amplified responses in primed astrocytes and neuronal network dysfunction.
    Alzheimers Dement. 2021 Jun 3. doi: 10.1002/alz.12341.
    >> Share

  260. TEMP AGM, Lutz MW, Trepel D, Tang Y, et al
    How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease.
    Alzheimers Dement. 2021;17:917-919.
    >> Share

  261. FRANZMEIER N, Ossenkoppele R, Brendel M, Rubinski A, et al
    The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Abeta-associated tau accumulation and cognitive decline.
    Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371.
    >> Share

  262. RICHARD E, den Brok MGHE, van Gool WA
    Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.
    Alzheimers Dement. 2021;17:1051-1055.
    >> Share

  263. DE ERAUSQUIN GA, Snyder H, Carrillo M, Hosseini AA, et al
    The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
    Alzheimers Dement. 2021;17:1056-1065.
    >> Share

    May 2021
  264. SEXTON CE, Anstey KJ, Baldacci F, Barnum CJ, et al
    Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12380.
    >> Share

  265. O'BRYANT SE, Zhang F, Petersen M, Hall JR, et al
    A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12382.
    >> Share

  266. PANNUZZO M
    Beta-amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12373.
    >> Share

  267. SCHWAHN C, Frenzel S, Holtfreter B, Van der Auwera S, et al
    Effect of periodontal treatment on preclinical Alzheimer's disease-Results of a trial emulation approach.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12378.
    >> Share

  268. RAJAN KB, Weuve J, Barnes LL, McAninch EA, et al
    Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12362.
    >> Share

  269. HAMPEL H, Shaw LM, Aisen P, Chen C, et al
    State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12372.
    >> Share

  270. JIANG Y, Zhou X, Ip FC, Chan P, et al
    Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
    Alzheimers Dement. 2021 May 25. doi: 10.1002/alz.12369.
    >> Share

  271. APOSTOLOVA LG, Aisen P, Eloyan A, Fagan A, et al
    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.
    Alzheimers Dement. 2021 May 21. doi: 10.1002/alz.12350.
    >> Share

  272. STERN Y, Stallard E, Kinosian B, Zhu C, et al
    Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12336.
    >> Share

  273. HONG S, Dobricic V, Ohlei O, Bos I, et al
    TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12330.
    >> Share

  274. LIBIGER O, Shaw LM, Watson MH, Nairn AC, et al
    Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12353.
    >> Share

  275. GUSTAVSSON A, Raket LL, Lilja M, Rutten-Jacobs L, et al
    Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12355.
    >> Share

  276. MORGAN DG, Mielke MM
    Knowledge gaps in Alzheimer's disease immune biomarker research.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12342.
    >> Share

  277. OSSENKOPPELE R, Hansson O
    Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12356.
    >> Share

  278. MADRASI K, Das R, Mohmmadabdul H, Lin L, et al
    Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Alzheimers Dement. 2021 May 2. doi: 10.1002/alz.12312.
    >> Share


  279. Association commits $14 million to novel drug trials in rare form of Alzheimer's.
    Alzheimers Dement. 2021;17:910.
    >> Share

  280. STANLEY J, Howlett SE, Dunn T, Rockwood K, et al
    The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Alzheimers Dement. 2021;17:856-865.
    >> Share

  281. MIELKE MM, Przybelski SA, Lesnick TG, Kern S, et al
    Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Alzheimers Dement. 2021;17:801-812.
    >> Share

  282. WOODWORTH DC, Nguyen HL, Khan Z, Kawas CH, et al
    Utility of MRI in the identification of hippocampal sclerosis of aging.
    Alzheimers Dement. 2021;17:847-855.
    >> Share

  283. COUSINS KAQ, Phillips JS, Irwin DJ, Lee EB, et al
    ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.
    Alzheimers Dement. 2021;17:822-830.
    >> Share

    April 2021
  284. RANASINGHE KG, Petersen C, Kudo K, Mizuiri D, et al
    Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 21. doi: 10.1002/alz.12349.
    >> Share

  285. LI X, Tsolis KC, Koper MJ, Ronisz A, et al
    Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 19. doi: 10.1002/alz.12345.
    >> Share

  286. BABILONI C, Arakaki X, Azami H, Bennys K, et al
    Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
    Alzheimers Dement. 2021 Apr 15. doi: 10.1002/alz.12311.
    >> Share

  287. MOELLER S, Sridhar J, Martersteck A, Coventry C, et al
    Functional decline in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 8. doi: 10.1002/alz.12331.
    >> Share

  288. MOLONEY CM, Lowe VJ, Murray ME
    Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12321.
    >> Share

  289. PROKOPENKO D, Morgan SL, Mullin K, Hofmann O, et al
    Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12319.
    >> Share

  290. SABBAGH MN, Cummings J
    Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
    Alzheimers Dement. 2021;17:702-703.
    >> Share

  291. KULLER LH, Lopez OL
    ENGAGE and EMERGE: Truth and consequences?
    Alzheimers Dement. 2021;17:692-695.
    >> Share

  292. BRAY MJC, Richey LN, Bryant BR, Krieg A, et al
    Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia.
    Alzheimers Dement. 2021;17:686-691.
    >> Share

  293. PLANCHE V, Bouteloup V, Mangin JF, Dubois B, et al
    Clinical relevance of brain atrophy subtypes categorization in memory clinics.
    Alzheimers Dement. 2021;17:641-652.
    >> Share

  294. STAFFARONI AM, Asken BM, Casaletto KB, Fonseca C, et al
    Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).
    Alzheimers Dement. 2021;17:574-583.
    >> Share

  295. KNOPMAN DS, Jones DT, Greicius MD
    Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Alzheimers Dement. 2021;17:696-701.
    >> Share

    March 2021
  296. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12332.
    >> Share

  297. SHI L, Winchester LM, Westwood S, Baird AL, et al
    Replication study of plasma proteins relating to Alzheimer's pathology.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12322.
    >> Share

  298. HANSSON O, Batrla R, Brix B, Carrillo MC, et al
    The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12316.
    >> Share


  299. Register for May AAIC(R) Satellite Symposium and second Latinos & Alzheimer's symposium.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12337.
    >> Share

  300. AKHTER-KHAN SC, Tao Q, Ang TFA, Itchapurapu IS, et al
    Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study.
    Alzheimers Dement. 2021 Mar 24. doi: 10.1002/alz.12327.
    >> Share


  301. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2021 Mar 23. doi: 10.1002/alz.12328.
    >> Share

  302. BECKMAN D, Chakrabarty P, Ott S, Dao A, et al
    A novel tau-based rhesus monkey model of Alzheimer's pathogenesis.
    Alzheimers Dement. 2021 Mar 18. doi: 10.1002/alz.12318.
    >> Share

  303. KOCIOLEK AJ, Fernandez KK, Jin Z, Cosentino S, et al
    Extrapyramidal signs and Alzheimer's disease prognosis in a multiethnic, community-based sample of demented elders.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12309.
    >> Share

  304. DISBROW E, Stokes KY, Ledbetter C, Patterson J, et al
    Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12305.
    >> Share

  305. FALGAS N, Walsh CM, Neylan TC, Grinberg LT, et al
    Deepen into sleep and wake patterns across Alzheimer's disease phenotypes.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12304.
    >> Share

  306. RAHMAN M, White EM, Mills C, Thomas KS, et al
    Rural-urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12285.
    >> Share

  307. SALVADO G, Mila-Aloma M, Shekari M, Minguillon C, et al
    Cerebral amyloid-beta load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12245.
    >> Share

  308. TURNER DA, Degan S, Hoffmann U, Galeffi F, et al
    CVN-AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12289.
    >> Share

  309. MASEREJIAN N, Krzywy H, Eaton S, Galvin JE, et al
    Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12280.
    >> Share

  310. SAITO ER, Miller JB, Harari O, Cruchaga C, et al
    Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression.
    Alzheimers Dement. 2021 Mar 2. doi: 10.1002/alz.12310.
    >> Share

  311. LI Y, Xiong C, Aschenbrenner AJ, Chang CH, et al
    Item response theory analysis of the Clinical Dementia Rating.
    Alzheimers Dement. 2021;17:534-542.
    >> Share

  312. FANI L, Ahmad S, Ikram MK, Ghanbari M, et al
    Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.
    Alzheimers Dement. 2021;17:446-456.
    >> Share

  313. GRANOT-HERSHKOVITZ E, Tarraf W, Kurniansyah N, Daviglus M, et al
    APOE alleles' association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).
    Alzheimers Dement. 2021;17:466-474.
    >> Share

    February 2021
  314. ASHFORD MT, Veitch DP, Neuhaus J, Nosheny RL, et al
    The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12253.
    >> Share

  315. BRICKMAN AM, Manly JJ, Honig LS, Sanchez D, et al
    Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12301.
    >> Share

  316. IZZO NJ, Yuede CM, LaBarbera KM, Limegrover CS, et al
    Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Alzheimers Dement. 2021 Feb 8. doi: 10.1002/alz.12302.
    >> Share

  317. BLEILE L
    Alzheimer's Association Update.
    Alzheimers Dement. 2021 Feb 4. doi: 10.1002/alz.12306.
    >> Share

  318. WANG R, Qiu C, Dintica CS, Shang Y, et al
    Shared risk and protective factors between Alzheimer's disease and ischemic stroke: A population-based longitudinal study.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12203.
    >> Share

  319. GUZMAN-VELEZ E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, et al
    Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12248.
    >> Share

  320. GRISWOLD AJ, Celis K, Bussies PL, Rajabli F, et al
    Increased APOE epsilon4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12287.
    >> Share

  321. HAGHANI A, Thorwald M, Morgan TE, Finch CE, et al
    The APOE gene cluster responds to air pollution factors in mice with coordinated expression of genes that differs by age in humans.
    Alzheimers Dement. 2021;17:175-190.
    >> Share

  322. CHEN XQ, Salehi A, Pearn ML, Overk C, et al
    Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Alzheimers Dement. 2021;17:271-292.
    >> Share

  323. BLUE EE, Thornton TA, Kooperberg C, Liu S, et al
    Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women.
    Alzheimers Dement. 2021;17:215-225.
    >> Share

  324. DE LEEUW FA, Karamujic-Comic H, Tijms BM, Peeters CFW, et al
    Circulating metabolites are associated with brain atrophy and white matter hyperintensities.
    Alzheimers Dement. 2021;17:205-214.
    >> Share

    January 2021
  325. AYTON S, Portbury S, Kalinowski P, Agarwal P, et al
    Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12282.
    >> Share

  326. SIMREN J, Leuzy A, Karikari TK, Hye A, et al
    The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12283.
    >> Share

  327. GERMANN J, Elias GJB, Boutet A, Narang K, et al
    Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12238.
    >> Share

  328. BRYAN J, Mandan A, Kamat G, Gottschalk WK, et al
    Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12223.
    >> Share

  329. LUCKETT PH, McCullough A, Gordon BA, Strain J, et al
    Modeling autosomal dominant Alzheimer's disease with machine learning.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12259.
    >> Share

  330. LI HD, Funk CC, McFarland K, Dammer EB, et al
    Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12254.
    >> Share


  331. Alzheimer's Association International Conference Neuroscience Next focused on early career researchers across all of neuroscience.
    Alzheimers Dement. 2021;17:138-139.
    >> Share

  332. CHIARI A, Vinceti G, Adani G, Tondelli M, et al
    Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy.
    Alzheimers Dement. 2021;17:81-88.
    >> Share

    December 2020
  333. VAN HULLE C, Jonaitis EM, Betthauser TJ, Batrla R, et al
    An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
    Alzheimers Dement. 2020 Dec 18. doi: 10.1002/alz.12204.
    >> Share

  334. LYSSENKO NN, Pratico D
    ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 17. doi: 10.1002/alz.12220.
    >> Share

  335. MOHAMMED H
    Recognizing African-American contributions to neurology: The role of Solomon Carter Fuller (1872-1953) in Alzheimer's disease research.
    Alzheimers Dement. 2020 Dec 15. doi: 10.1002/alz.12183.
    >> Share

  336. AUDRAIN M, Haure-Mirande JV, Mleczko J, Wang M, et al
    Reactive or transgenic increase in microglial TYROBP reveals a TREM2-independent TYROBP-APOE link in wild-type and Alzheimer's-related mice.
    Alzheimers Dement. 2020 Dec 12. doi: 10.1002/alz.12256.
    >> Share

  337. KIM YW, Al-Ramahi I, Koire A, Wilson SJ, et al
    Harnessing the paradoxical phenotypes of APOE varepsilon2 and APOE varepsilon4 to identify genetic modifiers in Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 7. doi: 10.1002/alz.12240.
    >> Share

  338. FRYE BM, Craft S, Register TC, Andrews RN, et al
    Diet, psychosocial stress, and Alzheimer's disease-related neuroanatomy in female nonhuman primates.
    Alzheimers Dement. 2020 Dec 3. doi: 10.1002/alz.12232.
    >> Share

    November 2020
  339. KARIKARI TK, Emersic A, Vrillon A, Lantero-Rodriguez J, et al
    Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Alzheimers Dement. 2020 Nov 30. doi: 10.1002/alz.12236.
    >> Share

  340. LLIBRE-GUERRA JJ, Li Y, Allegri RF, Mendez PC, et al
    Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12227.
    >> Share

  341. DUENAS MR, Snyder PJ
    Alzheimer's team care approach-akin to diabetes-in the development, validation, and population assessment of retinal biomarkers for disease.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12234.
    >> Share

  342. SPENCER BE, Digma LA, Jennings RG, Brewer JB, et al
    Gene- and age-informed screening for preclinical Alzheimer's disease trials.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12207.
    >> Share

  343. HITHERSAY R, Baksh RA, Startin CM, Wijeratne P, et al
    Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12222.
    >> Share

  344. PENTZ R, Iulita MF, Ducatenzeiler A, Videla L, et al
    Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12229.
    >> Share

  345. MONTAL V, Vilaplana E, Pegueroles J, Bejanin A, et al
    Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2020 Nov 16. doi: 10.1002/alz.12224.
    >> Share

  346. JESSEN F, Kleineidam L, Wolfsgruber S, Bickel H, et al
    Prediction of dementia of Alzheimer type by different types of subjective cognitive decline.
    Alzheimers Dement. 2020 Nov 2. doi: 10.1002/alz.12163.
    >> Share


  347. Alzheimer's Association pays tribute to former Chief Science Officer William (Bill) Thies, PhD.
    Alzheimers Dement. 2020;16:1600-1605.
    >> Share

    October 2020
  348. SOHEILI-NEZHAD S, van der Linden RJ, Olde Rikkert M, Sprooten E, et al
    Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12211.
    >> Share

  349. ARNSTEN AFT, Datta D, Tredici KD, Braak H, et al
    Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12192.
    >> Share

  350. WESSELS AM, Lines C, Stern RA, Kost J, et al
    Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 13. doi: 10.1002/alz.12164.
    >> Share

  351. MECCA AP, van Dyck CH
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    Alzheimers Dement. 2020 Oct 12. doi: 10.1002/alz.12190.
    >> Share

  352. SNYDER PJ, Alber J, Alt C, Bain LJ, et al
    Retinal imaging in Alzheimer's and neurodegenerative diseases.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12179.
    >> Share

  353. THUNELL J, Chen Y, Joyce G, Barthold D, et al
    Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12175.
    >> Share

  354. JAIN S, Rosenbaum PR, Reiter JG, Hoffman G, et al
    Using Medicare claims in identifying Alzheimer's disease and related dementias.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12199.
    >> Share

  355. HOU X, Watzlawik JO, Cook C, Liu CC, et al
    Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12198.
    >> Share

  356. BUBU OM, Umasabor-Bubu OQ, Turner AD, Parekh A, et al
    Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12184.
    >> Share

    September 2020
  357. FRANCESCO DL, Koch G
    Synaptic impairment: The new battlefield of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 18. doi: 10.1002/alz.12189.
    >> Share


  358. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 13. doi: 10.1002/alz.12172.
    >> Share

  359. JIA L, Xu H, Chen S, Wang X, et al
    The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12153.
    >> Share

  360. DE LEON J, Grasso SM, Welch A, Miller Z, et al
    Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12170.
    >> Share

    August 2020
  361. LIU CC, Yamazaki Y, Heckman MG, Martens YA, et al
    Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
    Alzheimers Dement. 2020 Aug 22. doi: 10.1002/alz.12104.
    >> Share

  362. FRISONI GB, Molinuevo JL, Altomare D, Carrera E, et al
    Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
    Alzheimers Dement. 2020 Aug 20. doi: 10.1002/alz.12132.
    >> Share

  363. FINSTERWALDER S, Vlegels N, Gesierich B, Araque Caballero MA, et al
    Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12150.
    >> Share

  364. LIN PJ, Cohen JT, Neumann PJ
    Preparing the health-care system to pay for new Alzheimer's drugs.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12155.
    >> Share

  365. DENNY A, Streitz M, Stock K, Balls-Berry JE, et al
    Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018.
    Alzheimers Dement. 2020 Aug 17. doi: 10.1002/alz.12160.
    >> Share

  366. WU CY, Ouk M, Wong YY, Anita NZ, et al
    Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
    Alzheimers Dement. 2020 Aug 16. doi: 10.1002/alz.12161.
    >> Share

  367. MOK VCT, Pendlebury S, Wong A, Alladi S, et al
    Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future.
    Alzheimers Dement. 2020 Aug 12. doi: 10.1002/alz.12143.
    >> Share

  368. JIA L, Zhu M, Kong C, Pang Y, et al
    Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
    Alzheimers Dement. 2020 Aug 10. doi: 10.1002/alz.12166.
    >> Share

  369. NHO K, Nudelman K, Allen M, Hodges A, et al
    Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.
    Alzheimers Dement. 2020 Aug 5. doi: 10.1002/alz.12092.
    >> Share

    July 2020
  370. GUSTAFSON DR, Backman K, Scarmeas N, Stern Y, et al
    Dietary fatty acids and risk of Alzheimer's disease and related dementias: Observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP).
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12154.
    >> Share

  371. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12137.
    >> Share

  372. VIDONI ED, Choi IY, Lee P, Reed G, et al
    Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12156.
    >> Share

  373. KLING MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, et al
    Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12110.
    >> Share

  374. XU W, Tan L, Su BJ, Yu H, et al
    Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study.
    Alzheimers Dement. 2020 Jul 13. doi: 10.1002/alz.12117.
    >> Share

    June 2020
  375. CASELLI RJ, Knopman DS, Bu G
    An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12124.
    >> Share

  376. LUTZ MW, Luo S, Williamson DE, Chiba-Falek O, et al
    Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12128.
    >> Share

  377. EREN E, Hunt JFV, Shardell M, Chawla S, et al
    Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12130.
    >> Share


  378. New Thinking About Thinking, Part 3. Advice on preparing a successful manuscript for Alzheimer's & Dementia.
    Alzheimers Dement. 2020 Jun 24. doi: 10.1002/alz.12141.
    >> Share

  379. MILA-ALOMA M, Salvado G, Gispert JD, Vilor-Tejedor N, et al
    Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12131.
    >> Share

  380. SHERVA R, Gross A, Mukherjee S, Koesterer R, et al
    Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12106.
    >> Share

  381. AZAR M, Chapman S, Gu Y, Leverenz JB, et al
    Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study.
    Alzheimers Dement. 2020 Jun 19. doi: 10.1002/alz.12120.
    >> Share

  382. SNYDER HM, Bain LJ, Brickman AM, Carrillo MC, et al
    Further understanding the connection between Alzheimer's disease and Down syndrome.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12112.
    >> Share

  383. SWERDLOW RH, Hui D, Chalise P, Sharma P, et al
    Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12119.
    >> Share

  384. COCROFT S, Welsh-Bohmer KA, Plassman BL, Chanti-Ketterl M, et al
    Racially diverse participant registries to facilitate the recruitment of African Americans into presymptomatic Alzheimer's disease studies.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12048.
    >> Share

  385. BERMEJO-PAREJA F, Del Ser T, Valenti M, de la Fuente M, et al
    Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12107.
    >> Share

  386. BI D, Wen L, Wu Z, Shen Y, et al
    GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12088.
    >> Share

  387. GENTREAU M, Chuy V, Feart C, Samieri C, et al
    Refined carbohydrate-rich diet is associated with long-term risk of dementia and Alzheimer's disease in apolipoprotein E epsilon4 allele carriers.
    Alzheimers Dement. 2020 Jun 7. doi: 10.1002/alz.12114.
    >> Share

  388. FIRTH NC, Primativo S, Brotherhood E, Young AL, et al
    Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression.
    Alzheimers Dement. 2020 Jun 2. doi: 10.1002/alz.12083.
    >> Share

    May 2020
  389. ORDING AG, Horvath-Puho E, Veres K, Glymour MM, et al
    Cancer and risk of Alzheimer's disease: Small association in a nationwide cohort study.
    Alzheimers Dement. 2020 May 20. doi: 10.1002/alz.12090.
    >> Share

  390. KNOPMAN D, Lemere CA, Lamb BT, Craft S, et al
    Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community.
    Alzheimers Dement. 2020 May 19. doi: 10.1002/alz.12059.
    >> Share

  391. RIOS-ROMENETS S, Lopera F, Sink KM, Hu N, et al
    Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
    Alzheimers Dement. 2020 May 17. doi: 10.1002/alz.12109.
    >> Share

  392. MECCA AP, Chen MK, O'Dell RS, Naganawa M, et al
    In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Alzheimers Dement. 2020 May 13. doi: 10.1002/alz.12097.
    >> Share

  393. MOORE EE, Gifford KA, Khan OA, Liu D, et al
    Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease.
    Alzheimers Dement. 2020 May 6. doi: 10.1002/alz.12087.
    >> Share

  394. RENTZ DM, Wessels AM, Bain LJ, Weber CJ, et al
    Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable.
    Alzheimers Dement. 2020;16:814.
    >> Share

    April 2020
  395. JORGENSEN IF, Aguayo-Orozco A, Lademann M, Brunak S, et al
    Age-stratified longitudinal study of Alzheimer's and vascular dementia patients.
    Alzheimers Dement. 2020 Apr 27. doi: 10.1002/alz.12091.
    >> Share

  396. DE FLORES R, Wisse LEM, Das SR, Xie L, et al
    Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease.
    Alzheimers Dement. 2020 Apr 22. doi: 10.1002/alz.12079.
    >> Share

  397. MURAOKA S, DeLeo AM, Sethi MK, Yukawa-Takamatsu K, et al
    Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues.
    Alzheimers Dement. 2020 Apr 17. doi: 10.1002/alz.12089.
    >> Share

  398. TRARES K, Gao X, Perna L, Rujescu D, et al
    Associations of urinary 8-iso-prostaglandin F2alpha levels with all-cause dementia, Alzheimer's disease, and vascular dementia incidence: results from a prospective cohort study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12081.
    >> Share

  399. LOPES ALVES I, Collij LE, Altomare D, Frisoni GB, et al
    Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12069.
    >> Share

  400. DONOHUE MC, Model F, Delmar P, Volye N, et al
    Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach.
    Alzheimers Dement. 2020 Apr 8. doi: 10.1002/alz.12058.
    >> Share

  401. GEERTS H, Spiros A
    Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.
    Alzheimers Dement. 2020 Apr 7. doi: 10.1002/alz.12082.
    >> Share

  402. CABALLERO MAA, Song Z, Rubinski A, Duering M, et al
    Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span.
    Alzheimers Dement. 2020;16:651-661.
    >> Share

    March 2020

  403. Alzheimer's Disease Research Enterprise in the Era of COVID-19/SARS-CoV-2.
    Alzheimers Dement. 2020 Mar 22. doi: 10.1002/alz.12093.
    >> Share


  404. 2020 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2020 Mar 10. doi: 10.1002/alz.12068.
    >> Share

  405. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2020;16:461-471.
    >> Share

  406. LOWE VJ, Lundt ES, Albertson SM, Min HK, et al
    Tau-positron emission tomography correlates with neuropathology findings.
    Alzheimers Dement. 2020;16:561-571.
    >> Share

  407. PAPP KV, Buckley R, Mormino E, Maruff P, et al
    Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
    Alzheimers Dement. 2020;16:552-560.
    >> Share

    February 2020
  408. XIONG C, Luo J, Coble D, Agboola F, et al
    Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.
    Alzheimers Dement. 2020 Feb 17. doi: 10.1002/alz.12060.
    >> Share

  409. SCHAFFERT J, LoBue C, White CL 3rd, Wilmoth K, et al
    Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12049.
    >> Share

  410. FRANZMEIER N, Koutsouleris N, Benzinger T, Goate A, et al
    Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12032.
    >> Share


  411. Bill Gates funds $10 million grant to Alzheimer's Association to fuel research for Alzheimer's treatment.
    Alzheimers Dement. 2020;16:384.
    >> Share

  412. ANTONELL A, Tort-Merino A, Rios J, Balasa M, et al
    Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Alzheimers Dement. 2020;16:262-272.
    >> Share

  413. ANGULO SL, Henzi T, Neymotin SA, Suarez MD, et al
    Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites.
    Alzheimers Dement. 2020;16:251-261.
    >> Share

    January 2020
  414. HERRING WJ, Ceesay P, Snyder E, Bliwise D, et al
    Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Alzheimers Dement. 2020 Jan 15. doi: 10.1002/alz.12035.
    >> Share

  415. JIA L, Fu Y, Shen L, Zhang H, et al
    PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease.
    Alzheimers Dement. 2020;16:178-191.
    >> Share

  416. SNYDER PJ, Snyder HM, Bain LJ
    Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's.
    Alzheimers Dement. 2020;16:244.
    >> Share

  417. ALBER J, Goldfarb D, Thompson LI, Arthur E, et al
    Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward.
    Alzheimers Dement. 2020;16:229-243.
    >> Share

  418. PATHAK GA, Zhou Z, Silzer TK, Barber RC, et al
    Two-stage Bayesian GWAS of 9576 individuals identifies SNP regions that are targeted by miRNAs inversely expressed in Alzheimer's and cancer.
    Alzheimers Dement. 2020;16:162-177.
    >> Share

  419. ASCHENBRENNER AJ, James BD, McDade E, Wang G, et al
    Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN).
    Alzheimers Dement. 2020;16:219-228.
    >> Share

  420. LINARD M, Letenneur L, Garrigue I, Doize A, et al
    Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.
    Alzheimers Dement. 2020;16:200-208.
    >> Share

  421. KAPLOW J, Vandijck M, Gray J, Kanekiyo M, et al
    Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status.
    Alzheimers Dement. 2020;16:144-152.
    >> Share

    December 2019
  422. ELAHI FM, Casaletto KB, La Joie R, Walters SM, et al
    Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35373.
    >> Share

  423. SABBAGH M, Sadowsky C, Tousi B, Agronin ME, et al
    Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35367.
    >> Share

    November 2019
  424. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35487.
    >> Share

  425. ANDREWS SJ, Goate A, Anstey KJ
    Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35486.
    >> Share

  426. GONZALEZ HM, Tarraf W, Fornage M, Gonzalez KA, et al
    A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: Design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA).
    Alzheimers Dement. 2019 Nov 20. pii: S1552-5260(19)35362.
    >> Share

  427. TOLAR M, Abushakra S, Sabbagh M
    The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
    Alzheimers Dement. 2019 Nov 4. pii: S1552-5260(19)35450.
    >> Share


  428. Corrigendum to "AMYPAD Diagnostic and Patient Management Study: Rationale and design" [Alzheimer's & Dementia 2019;15:388-99].
    Alzheimers Dement. 2019;15:1505.
    >> Share

    October 2019
  429. ISAACSON RS, Hristov H, Saif N, Hackett K, et al
    Individualized clinical management of patients at risk for Alzheimer's dementia.
    Alzheimers Dement. 2019 Oct 31. pii: S1552-5260(19)35368.
    >> Share

  430. PULINA MV, Hopkins M, Haroutunian V, Greengard P, et al
    C99 selectively accumulates in vulnerable neurons in Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 30. pii: S1552-5260(19)35370.
    >> Share

  431. OSSENKOPPELE R, Lyoo CH, Sudre CH, van Westen D, et al
    Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 28. pii: S1552-5260(19)35375.
    >> Share

  432. BROSSERON F, Kolbe CC, Santarelli F, Carvalho S, et al
    Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.
    Alzheimers Dement. 2019 Oct 17. pii: S1552-5260(19)35352.
    >> Share

  433. STOCKER H, Nabers A, Perna L, Mollers T, et al
    Prediction of Alzheimer's disease diagnosis within 14 years through Abeta misfolding in blood plasma compared to APOE4 status, and other risk factors.
    Alzheimers Dement. 2019 Oct 11. pii: S1552-5260(19)35349.
    >> Share

  434. GLEASON CE, Norton D, Zuelsdorff M, Benton SF, et al
    Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center.
    Alzheimers Dement. 2019 Oct 6. pii: S1552-5260(19)35138.
    >> Share

  435. OGINO E, Manly JJ, Schupf N, Mayeux R, et al
    Current and past leisure time physical activity in relation to risk of Alzheimer's disease in older adults.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35136.
    >> Share

  436. EHRHARDT S, Porsteinsson AP, Munro CA, Rosenberg PB, et al
    Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35112.
    >> Share

    September 2019
  437. MCRAE-MCKEE K, Udeh-Momoh CT, Price G, Bajaj S, et al
    Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?
    Alzheimers Dement. 2019 Sep 26. pii: S1552-5260(19)35133.
    >> Share

  438. BLUE EE, Horimoto ARVR, Mukherjee S, Wijsman EM, et al
    Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics.
    Alzheimers Dement. 2019 Sep 25. pii: S1552-5260(19)35348.
    >> Share

  439. SCHAEFER KR, Noonan C, Mosley M, Smith J, et al
    Differences in service utilization at an urban tribal health organization before and after Alzheimer's disease or related dementia diagnosis: A cohort study.
    Alzheimers Dement. 2019 Sep 20. pii: S1552-5260(19)35111.
    >> Share

    August 2019
  440. MC ARDLE R, Galna B, Donaghy P, Thomas A, et al
    Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?
    Alzheimers Dement. 2019 Aug 30. pii: S1552-5260(19)35120.
    >> Share

  441. ELDADAH BA, Fazio EM, McLinden KA
    Lucidity in dementia: A perspective from the NIA.
    Alzheimers Dement. 2019;15:1104-1106.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016